Iltria (Ramipril, Acetylsalicylic Acid, Atorvastatin Calcium Trihydrate)

Iltria combines three agents that act on blood pressure, platelet function and lipid metabolism, providing a broad approach to cardiovascular disease management.

• Hypertension: lowers systemic blood pressure and reduces cardiac workload.
• Hyperlipidemia: decreases LDL‑cholesterol and total cholesterol levels.
• Primary and secondary prevention of cardiovascular events: reduces the risk of myocardial infarction, stroke and other atherothrombotic complications.
• Post‑myocardial infarction prophylaxis: supports long‑term protection against recurrent cardiac events.

• Ramipril blocks the angiotensin‑converting enzyme, decreasing angiotensin II formation and vasoconstriction. Acetylsalicylic acid irreversibly inhibits cyclooxygenase‑1, limiting thromboxane A2 synthesis and platelet aggregation. Atorvastatin calcium trihydrate competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis, leading to reduced circulating LDL‑cholesterol. The three mechanisms act synergistically to control blood pressure, prevent clot formation, and improve lipid profiles.

Adverse reactions may occur with any component of the fixed‑dose combination.

Common Side Effects

• Cough or mild throat irritation.
• Headache or dizziness.
• Gastrointestinal discomfort such as nausea or dyspepsia.
• Minor bruising or prolonged bleeding from minor cuts.
• Muscle aches or mild weakness.
• Elevated liver enzymes without clinical symptoms.

Serious or Rare Side Effects

• Angioedema or severe swelling of the face, lips or tongue.
• Significant bleeding or gastrointestinal hemorrhage.
• Rhabdomyolysis with muscle breakdown and dark urine.
• Acute liver injury presenting with jaundice.
• Severe hypotension causing fainting.
• Allergic reactions such as rash, itching or anaphylaxis.

Before initiating therapy, consider patient‑specific factors and monitor relevant parameters.

• Renal function: assess creatinine clearance and adjust if necessary.
• Hepatic function: evaluate liver enzymes, especially when atorvastatin is used.
• Bleeding risk: avoid in patients with active ulcers or coagulopathies.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; consult a specialist.
• Drug allergies: verify no hypersensitivity to ACE inhibitors, aspirin or statins.
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Drug interactions can modify efficacy or increase toxicity.

Major Interactions (Avoid)

• Potassium‑sparing diuretics or supplements: risk of hyperkalaemia with ramipril.
• Other anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk with aspirin.
• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may raise atorvastatin plasma levels and precipitate myopathy.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect.
• Diuretics: may enhance hypotensive response.
• Fibrates: combined lipid‑lowering therapy can increase risk of muscle toxicity.
• Lithium: ACE inhibition can raise lithium concentrations.
• Antacids containing aluminium or magnesium: may reduce absorption of ramipril.